Brokerages Set Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY) PT at $15.67

Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY) has earned an average recommendation of “Buy” from the six research firms that are currently covering the company, Marketbeat reports. Five investment analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $15.6667.

Several equities research analysts have commented on BWAY shares. Weiss Ratings reiterated a “buy (b-)” rating on shares of Brainsway in a research note on Tuesday. Wall Street Zen downgraded Brainsway from a “buy” rating to a “hold” rating in a research report on Saturday. BTIG Research initiated coverage on shares of Brainsway in a research note on Monday, July 20th. They set a “buy” rating and a $18.00 target price on the stock. Zacks Research raised Brainsway from a “hold” rating to a “strong-buy” rating in a research note on Monday, July 13th. Finally, New Street Research restated a “buy” rating on shares of Brainsway in a research report on Friday.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Y.D. More Investments Ltd grew its stake in shares of Brainsway by 136.6% in the 1st quarter. Y.D. More Investments Ltd now owns 272,004 shares of the company’s stock valued at $3,615,000 after purchasing an additional 157,042 shares during the last quarter. Sigma Planning Corp raised its stake in shares of Brainsway by 369.1% during the first quarter. Sigma Planning Corp now owns 70,363 shares of the company’s stock worth $935,000 after purchasing an additional 55,363 shares during the last quarter. Sei Investments Co. raised its stake in shares of Brainsway by 262.5% during the first quarter. Sei Investments Co. now owns 226,378 shares of the company’s stock worth $3,009,000 after purchasing an additional 163,925 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in shares of Brainsway by 87.2% during the first quarter. Renaissance Technologies LLC now owns 518,420 shares of the company’s stock worth $6,890,000 after purchasing an additional 241,560 shares during the period. Finally, Ballast Advisors LLC acquired a new stake in shares of Brainsway during the first quarter worth $55,000. 30.11% of the stock is owned by institutional investors and hedge funds.

Brainsway Price Performance

Brainsway stock opened at $15.97 on Monday. Brainsway has a 1-year low of $5.68 and a 1-year high of $17.35. The stock has a market capitalization of $640.86 million, a price-to-earnings ratio of 45.63 and a beta of 1.22. The business has a fifty day moving average price of $15.02 and a 200-day moving average price of $13.95.

Brainsway (NASDAQ:BWAY) last announced its quarterly earnings data on Wednesday, May 13th. The company reported $0.12 earnings per share for the quarter, beating analysts’ consensus estimates of $0.05 by $0.07. The firm had revenue of $15.53 million for the quarter, compared to analyst estimates of $14.63 million. Brainsway had a net margin of 15.68% and a return on equity of 12.28%. On average, equities research analysts anticipate that Brainsway will post 0.33 earnings per share for the current fiscal year.

About Brainsway

Brainsway Ltd is a medical device company specializing in non-invasive neuromodulation therapies. Publicly traded on the NASDAQ under the symbol BWAY, the company develops and commercializes deep transcranial magnetic stimulation (Deep TMS) systems designed to treat a range of neuropsychiatric and neurological disorders. Brainsway’s technology aims to offer an alternative or complement to traditional pharmacological therapies by targeting precise brain regions with its patented coil designs.

The company’s flagship Deep TMS platform utilizes proprietary H-coil arrays engineered to reach deeper cortical structures than conventional TMS devices.